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Abstract 
 
 
A CONTINUOUS PROCESS TOWARDS THE SYNTHESIS QUINOLONES 
By Stevara N. Clinton, M.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of 
Master or Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 2015 
Major Director: B. Frank Gupton, Research Professor and Chair, Department of 
Chemical and Life Sciences Engineering 
 
 The development of quinolones is described from the first quinolone to 
the latest fluoroquinolones.  Quinolones have generated considerable interest 
since their discovery because of their antibacterial capabilities.  Analogs 
incorporating the 4-quinolone ring system comprise a largely expanding group of 
synthetic compounds.  The development of antibacterial resistance has created 
the need for an efficient synthesis of quinolones that can be easily adapted 
toward the assembly of quinolone based antibacterial drugs. 
 There are several reported approaches to the 4-quinolone ring system.  
Many of these methods use expensive starting materials, require the removal of 
high boiling solvents, or use high temperature conditions (>200°C) for the final 
cyclization.  Our synthesis of 4-quinolones was achieved via continuous flow 
chemistry using inexpensive starting materials in easily removable solvents, and 
under mild conditions. 
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 Flow chemistry is the use of technology that allows a continuous flow of 
reagents to be introduced at various points along a process stream, enabling 
interaction under highly controlled conditions.  By employing this technology we 
achieved a more rapidly scalable synthesis of 4-quinolones, offering safer 
reacting conditions and highly reproducible results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   iv	  
 
 
Acknowledgements 
 
 
 I want to thank my husband first, for his love and support throughout my 
years of graduate study.  Thank you for standing by me and being my pillar of 
strength. 
 To my advisor, Dr. B. Frank Gupton, I thank you for your advice.  I am 
grateful for the training and knowledge I have received during my time as a 
member of your research group. 
 To Dr. Katherine Belecki, thank you for all of the additional help and 
knowledge that you have enriched my life with since coming to VCU. 
 To my laboratory colleagues, thank you for your camaraderie and support. 
 Finally, to my committee members thank you for your suggestions and 
encouragement throughout my studies. 
 
 
 
 
 
 
 
 
 
	   v	  
 
Table of Contents 
 
Abstract ii 
Acknowledgements iv 
List of Tables viii 
List Figures viiii 
List of Schemes x 
Abbreviations xii 
Chapter 1 4(1H)-Quinolones 13 
1.0 Overview 13 
1.1 Introduction 13 
1.2 History of Quinolones 14 
1.3 Mechanism of Action 18 
1.4 Classical Formations of Quinolones 18 
1.4.1 Gould-Jacob’s synthesis 18 
1.4.2 Conrad-Limpach synthesis 19 
1.4.3 Camps synthesis 20 
1.4.4 Biere-Seelen synthesis 21 
1.4.5 Snieckus synthesis 22 
1.4.6 Dieckman cyclization  22 
1.5 Alternate Uses of Quinolones 23 
	   vi	  
1.5.1 Quinolones as anti-cancer agents 23 
1.5.2 Quinolones as HIV inhibitors 23 
1.5.3 Quinolones as anti-anxiety agents 24 
Chapter 2  Ciprofloxacin 25 
2.0 Overview 25 
2.1 Introduction 25 
2.2 Previous Syntheses of Ciprofloxacin 25 
2.2.1 Bayer synthesis 26 
2.2.2 Schwalbe et. al synthesis 27 
Chapter 3 Studies Toward the Synthesis of Ciprofloxacin 28 
3.0 Overview 28 
3.1 Background 28 
3.2 Initial Synthetic Studies 31 
3.2.1 Preparation of 2,4-dichloro-5-fluoroacetophenone 
derivatives 
31 
3.2.2 Addition of cyclopropylamine and benzylamine 33 
3.3 Preparation of Nitroacetophenone Derivatives  36 
3.4 Preparation of Enaminone 70 and Transamination Studies 36 
3.5 Ring Closure through Reduction 38 
3.6 Application to the Synthesis of Ciprofloxacin and Other 
Antibacterial Derivatives 
40 
3.6.1 Halogenation of the 4-quinolone at the 3-position 41 
	   vii	  
3.6.2 Methylation of the amine 42 
Chapter 4 Experimental 43 
4.1 General Remarks 43 
4.2 Experiments Pertaining to the Starting Reagent 2,4-Dichloro-5-
fluoroacetophenone 
43 
4.3 Experiments Pertaining to the Starting Reagent 
Nitroacetophenone 
47 
4.4 Experiments Pertaining to Modification of the 4-Quinolone 49 
Chapter 5 Conclusion 51 
References 52 
 
 
 
 
 
 
 
 
 
 
 
 
	   viii	  
 
List of Tables 
 
Tables Page 
1. Reaction studies for the addition of DMF-DMA to 2,4-dichloro-5-
fluoroacetophenone. 
32 
2.  Amine exchange reaction studies with CPA 34 
3.  H-cube reaction studies 40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   ix	  
 
List of Figures 
 
Figures Page 
1.  4-quinolone core structure with numbering 14 
2.  Flouroquinolone core structure 14 
3.  Nalidixic acid and naphthyridine core structure 15 
4.  First generation of quinolone antibacterials 15 
5.  Second generation of quinolone antibacterials 16 
6.  Third generation of quinolone antibacterials 17 
7.  Fourth generation of quinolone antibacterials 17 
8.  Quinolone derivative exhibiting antiviral activity 24 
9.  FDA pproved quinolone anti-anxiety drug, Elvitegravir 24 
10.  Formates used in initial study 32 
11.  Vapourtec flow reactor 37 
  
 
 
 
 
 
 
	   x	  
List of Schemes 
Schemes Page 
1.  Gould-Jacobs reaction 17 
2.  Conrad-Limpach quinolone synthesis 18 
3.  Camps quinoline synthesis 18 
4.  Biere-Seelen synthesis 19 
5.  Snieckus synthesis of 4-quinolones 20 
6.  Dieckmann Cyclization approach to 4-quinolones 20 
7.  Bayer Ciprofloxacin synthesis 24 
8.  Schwalbe Ciprofloxacin synthesis 25 
9. Overview of the initial synthesis of the carboxylated quinolone to 
Ciprofloxacin 
27 
10.  2,4-dichloro-5-fluoroacetophenone and DMF-DMA reaction 31 
11.  Amine exchange with CPA 32 
12.  Revised route to the carboxylate quinolone 33 
13.  Amine exchange with benzylamine 34 
14.  Synthesis of enaminone 70 35 
15.  Amine exchange with CPA on enaminone 70 36 
16.  H-cube schematic 37 
17.  H-cube quinolone synthesis 37 
18.  Bromination of the 4-quinolone 39 
19.  Iodination of the 4-quinolone 39 
	   xi	  
20.  Attempted route for methylation of the amine at the 1-position 40 
21.  Attempted route for methylation of the amine at the 1-position 40 
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
	   xii	  
Abbreviations 
AcOH Acetic acid 
Cipro Ciprofloxacin 
CHCl3 Chloroform 
CH3I Methyl Iodide 
DMF N,N-Dimethylformamide 
DMF-DMA N,N-Dimethylformamide dimethyl acetal 
Et3N Triethylamine 
HCl Hydrochloric acid 
KOH Potassium hydroxide 
MeOH Methanol 
NaOH Sodium hydroxide 
NMP N-methyl-2-pyrrolidone 
NMR Nuclear Magnetic Resonance 
TEA Triethylamine 
THF Tetrahydrofuran 
  
	   13	  
 
Chapter 1 
4(1H)-Quinolones 
 
1.0 Overview 
This thesis describes the development of a novel methodology for the 
synthesis of 4-quinolones, as well as their application towards the synthesis of 
marketed and new antibacterial drugs.  The primary purpose of this chapter is to 
provide background on previous syntheses leading to 4-quinolones and their 
relevant biological activity. 
1.1 Introduction 
In the area of antibiotics, the 4-quinolone ring system 1 has been heavily 
studied and is an attractive synthetic target in organic synthesis.1  It is well 
represented in numerous natural product structures as the core structural motif 
of many antibacterial agents. 
Defined by a bicyclic heteroaromatic core, quinolones require an R-
substitued nitrogen at the 1-position and a carbonyl at the C4-position.2  The 
most popular 4-quinolones are the fluoroquinolones 2 (6-fluoro-4-quinolone-3-
carboxylic acid).3  They display high activity against a broad range of bacteria.  
They are so popular, in fact, that most literature refers to them as simply 
“quinolones” while other 4-quinolones are specifically identified as non-
fluorinated or non-carboxylated quinolones.  It is these non-flourinated and non-
	   14	  
carboxylated quinolone that have attracted interest as anti-cancer drugs, HIV 
inhibitors, and anti-anxiety agents.4-6 
 
 
1 
Figure 1.  4-Quinolone core structure with numbering 
 
2 
Figure 2.  Fluoroquinolone core structure 
 
1.2 History of Quinolone 
Historically, the quinolone era began in 1962 with the introduction of the 
quinolone precursor nalidixic acid 3.  This naphthyridine (4) agent was 
discovered as a byproduct in the course of a chloroquine synthesis and was 
found to moderately inhibit gram-negative bacteria growth leading to its use as a 
treatment for urinary tract infections (UTIs).7,8 
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                 3                              4 
Figure 3.  Nalidixic acid and naphthyridine core structure 
 
Over the next two decades, several variations to the naphthyridine scaffold were 
investigated leading to the first generation of quinolone antibiotics shown in 
Figure 4. 
 
5        6 
 
7       8 
Figure 4.  First generation of quinolone antibacterials 
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Lack of broad activity against bacteria and rapid resistance to the early 
quinolones eventually led to the preparation of 6-fluoro derivatives.8,9  From 
there the second, third and fourth generations were introduced (Figures 5-7), 
which quickly addressed the narrow spectrum of activity previously seen.  
Ciprofloxacin, patented by Bayer in 1983, is the most successful of this class and 
has been prescribed worldwide;  it is often employed as a drug of last resort 
when other antibiotics fail.9,10,11 
 
9             10                       11 
 
12        13                   14 
 
15             16                       17 
Figure 5.  Second generation of quinolone antibacterials 
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17              18                            19 
 
20              21                         22 
Figure 6.  Third generation of quinolone antibacterials 
 
 
23              24                         25 
Figure 7.  Fourth generation of quinolone antibacterials 
 
The later generations all have the following aspects in common: identical core 4-
quinolone ring structure and identical mechanisms of action. 
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1.3 Mechanism of Action 
Mechanistically, quinolones work by inhibiting the bacterial DNA replication 
process.  Topoisomerase is an enzyme used in the replication process to unwind 
and cleave the bacterial DNA strand allowing the single strand to be read and 
complemented with a new second strand, thus restoring coiling and replicating 
the bacteria genome.  The quinolone impedes this action by inhibiting the 
topisomerase from unwinding, thereby disrupting DNA replication, and 
furthermore, cell viability.12,13 
 
1.4 Classical Formations of Quinolones 
 
1.4.1  Gould-Jacobs synthesis of quinolones 
The Gould-Jacobs method is one of the most popular and well established 
methods for the synthesis of quinolones.  This method is based upon an 
addition-elimination reaction between anilines such as 26 and ethyl 
ethoxymethyenemalonate 27 to yield intermediate 28, as shown in Scheme 1.  
These intermediates then undergo thermal cyclization at high temperatures to 
give the 4(1H)-quinolone system 29.14,15 
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26                    27        28 
           
    29 
Scheme 1.  Gould-Jacobs reaction 
 
1.4.2 Conrad-Limpach synthesis 
 This reaction involves the condensation of an aniline 26 with an 
acetoacetic ester 30 to yield a Schiff base intermediate 31.  The intermediate 
then undergoes tautomerization before thermal cyclization (250°C) to yield 4-
quinolone derivative  33 shown in Scheme 2.16 
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    26                30                31 
                                  
                            33                                    32 
Scheme 2.  Conrad-Limpach quinolone synthesis 
 
1.4.3 Camps quinoline synthesis 
 In this synthesis, an o-acetylaminoacetophenone 34 is cyclized in the 
presence of a hydroxide ion to yield two hydroxylquinolines 35 and 36 in the 
proportion of 70:20 respectively (Scheme 3).17-22 
 
               34                                        35                                  36 
Scheme 3.  Camps quinoline synthesis 
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1.4.4  Biere-Seelen synthesis 
 The Biere and Seelen approach for quinolone synthesis was developed in 
1979.23  The procedure involves a Michael addition that gives rise to enamino 
ester 39.  The ester then undergoes cyclization (product 40) in the presence of 
a strong base followed by either complete or regioselective hydrolysis to achieve 
the dicarboxylic acid 41 and the ester acid 42.  Thermal decarboxylation of the 
ester acid 42 gives the carboxyl quinolone 43. 
 
 
37     38        39 
 
    40            41   42 
                   
                 43 
Scheme 4.  Biere-Seelen synthesis. 
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1.4.5  Snieckus synthesis 
The Snieckus group has published one of the few methods for 3-alkyl-substitued 
4-quinolones.  They synthesized 4-quinolones by the condensation of an ortho-
substituted aniline 44 with a ketone 45.  This was followed by deprotonation 
and intramolecuar cyclization using a strong hindered base to yield quinolone 
47.24 
 
      44    45       46          47 
Scheme 5.  Snieckus synthesis of 4-quinolones 
 
1.4.6  Dieckmann cyclization 
This process involves a diester 48 which undergoes intramolecular ring closure in 
the presence of a base to form the dihydroquinolone 49.  Oxidation of 49 yields 
the 4-quinolone 50.25 
 
48           49      50 
Scheme 6.  Dieckmann cyclization approach to 4-quinolones 
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1.5 Alternate Uses of Quinolones 
 
1.5.1  Quinolones as anti-cancer agents 
 As mentioned, quinolones are well known for their antibacterial activity 
which arises from interferance with the DNA replication process in bacterial cells.  
However, in addition to killing bacterial cells, they have the added benefit of 
killing cancerous tumor cells as well.26,27  It has been found that some current 
anti-tumor drugs (topotecan and amsacrine) exhibit the same mechanism of 
action as fluoroquinolones.28  None have been approved for use yet because they 
are not at targeted as currently used chemotherapy drugs.  However, quinolones 
are effective cell killers and are therefore being studied further for their 
effectiveness in stopping the multiplication of cancerous cells. 
 
1.5.2  Quinolones as HIV inhibitors 
 New research is being pursued to find alternate treatments for HIV to 
overcome the emergence of resistance to current treatments.  Baba and 
coworkers were one of the first to discover that some antibacterial 
fluoroquinolones can exhibit antiviral activity.29  A further study lead by Cecchetti 
and coworkers discovered a quinolone derivative that exhibits good antiviral 
activity (Figure 8).30  These discoveries play a crucial role in ongoing efforts to 
find a treatment that can suppress HIV replication using quinolones. 
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51 
Figure 8.  Quinolone derivative exhibiting antiviral activity 
 
1.5.3  Quinolones as anti-anxiety agents 
 Anxiety is defined as a nervous disorder characterized by a state of 
excessive uneasiness and apprehension.  Kahnberg et al. found a quinolone 
derivative that worked effectively as an anti-anxiety agent leading to the 
discovery of others (Figure 9); some of which show comparable results to known 
anti-anxiety drugs currently prescribed.31  These quinolones are found to work by 
binding to the receptor sites in the brain that regulate anxiety much the same as 
some current treatments. 
 
52 
Figure 9.  FDA pproved quinolone anti-anxiety drug, Elvitegravir 
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Chapter 2 
Ciprofloxacin 
 
2.0 Overview 
 Our interest in 4-quinolones originally grew out of an early approach 
toward the synthesis of ciprofloxacin.  In this chapter we introduce ciprofloxacin 
and provide background on previous synthetic work leading to its preparation.  
This methodology is related, in that Ciprofloxacin requires a quinolone framework 
for synthesis. 
 
2.1 Introduction 
The widely marketed antibiotic ciprofloxacin (Cipro) 9 was discovered and 
developed by Bayer A.G. in 1983.32  It is approved for use for a wide range of 
bacterial infections and is the most successful of the fluoroquinolones.  Cipro 
gained notoriety in the early 2000’s during the onset of bioterrorist attacks and 
was labeled as the drug of choice in the treatment of anthrax exposures.33 
 
2.2 Previous Syntheses of Ciprofloxacin 
 Two well known total syntheses of Cipro appear in the literature.  One is 
the patented method by Bayer A. G. and the other a continuous method 
patented in 2001 by Schwalbe and coworkers.34,35 
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2.2.1 Bayer A.G. Synthesis (1983) 
 In an effort to improve the antibiotic activity of the norfloxacin stucture, a 
Bayer scientist, Dr. Klaus Grohe sought out to construct other quinolone analogs.  
He discovered exceptional antibacterial activity when the quinolone core was 
substituted with cyclopropylamine and piperzine.36,37  The synthesis involves an 
acid halide 53 reacted with a dimethylaminoacrylic acid ester 54.  The resulting 
aminoacrylic ester 55 is then converted to compound 57 by an amine exchange 
with cyclopropylamine 56.  A base is introduced, and the compound is cyclized 
to form quinolone 58.  The addition of piperzine at the 7-position  and hydrolysis 
of the ethyl ester provided ciprofloxacin 9 (Scheme 7). 
 
      53                  54       55 
 
            56                  57     58   
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Scheme 7.  Bayer Ciprofloxacin synthesis32 
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2.2.2  Schwalbe et. Al Synthesis (2001) 
 In 2001, Schwalbe reported a synthesis of ciprofloxacin using a 
microreactor system (Scheme 8).  This feat successfully demonstrated a complex 
multi-step synthesis performed in continuous flow.35  As in the Bayer synthesis, 
Schwalbe starts with the reaction of 2,4,5-trifluorobenzoic acid chloride and 
dimethylaminoacrylic acid ester, followed by an amine exchange with 
cyclopropylamine and subsequent nucleophilic ring closure to give the 
difluoroquinolone ring system 58.  A substitution and hydrolysis then affords the 
target product. 
 
 
         53                       54              55 
 
 
               56                    57         58 
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Scheme 8.  Schwalbe Ciprofloxacin synthesis38 
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Chapter 3 
Studies Toward the Synthesis of Ciprofloxacin 
 
3.0 Overview 
 At the beginning of this project, we had two main goals.  First, we wished 
to develop an efficient and novel synthesis of carboxylated quinolones.  Ideally, 
we hoped to achieve this by using 2,4-dichloro-5-fluoroacetophenone and 
treating with a formate in flow. Then, we would carry out subsequent steps in 
flow as well, with a key step highlighting CH activation for the direct activation 
and carbonylation of the quinolone at the 3-position.  Secondly, we hoped to use 
this methodology in a total synthesis of Ciprofloxacin.  Our proposed initial 
synthesis is shown later in Scheme 9. 
 When our formate approach failed, and due to difficulties in the addition 
of a cyclic amine, we developed several other routes, one which successfully led 
to the 4-quinolone synthesis we present here.  The details of the studies that led 
to this synthesis are described in this chapter. 
 
3.1 Background 
 Despite the functional design of the synthesis previously described, there 
is still room for improvement.  Of the quinolone syntheses, the two most 
commonly used, the Gould-Jacobs and Conrad-Limpach, undergo high 
temperature conditions (>200°C) for the final cyclization, have poor 
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regioselectivity, produce diphenyl ureas byproducts and have problems with tar 
formation.39,40  The Bayer Cipro synthesis is lengthy and requires significant time 
to complete the entire multistep process in batch.  In the Schwalbe synthesis, 
although faster and therefore more ideal, requires expensive starting materials. 
  There is particular focus on accessing the 4-quinolone ring structure, since 
even the simplest forms of this structure show useful biological activity.41  
Furthermore, there are relatively few synthetic routes to quinolones that do not 
require the use of harsh reactions conditions, indicating the need for a mild and 
efficient route. 
 The research presented herein is directed towards developing a novel and 
efficient synthesis of quinolones that can be easily adapted toward the assembly 
of quinolone-based antibacterial agents.  The demand for novel antibacterial 
drugs continues to grow as more bacteria become resistant to current 
treatments.2 This demand has driven the need to develop a route for the 
preparation of antibiotics that can be altered to produce modified derivatives.  By 
applying continuous flow technology, we aim to overcome the limitations of 
previous approaches by avoiding the use of expensive starting materials and 
reactions that are not practical for large-scale use.  Furthermore this route will 
allow us to access known and new analogues by applying this route to synthesize 
other agents. 
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Flow Chemistry 
Flow chemistry was introduced about 12 years ago in synthesis 
laboratories.42 This technology allows a continuous flow of reagents to be 
introduced at various points along a process stream, enabling interaction under 
highly controlled conditions.  Flow systems allow high throughput chemistry to 
take place, often employing immobilized reagents or catalysts.43  
When compared to batch processes, flow processes have minimal scale-up 
issues.  Instead of scaling up for mass production by increasing reactor size as 
with batch processes, flow reactors can be scaled up by introducing more 
reactors in parallel (scaling out) while maintaining excellent mixing and heat 
transfer.44,45  The reduction in plant size while increasing plant production is 
known as process intensification. Carrying out a reaction in flow on a laboratory 
scale can have the advantage of faster reaction times, safer conditions and faster 
optimization.46  For example, a reaction that may require a 24-hour reflux in 
batch could be reduced to 20 minutes in a continuous flow process.  Reaction 
times, temperature, reagents, pressure, and flow rates can all be rapidly varied 
to achieve the best conditions.  Furthermore, some batch processes pose 
operational hazards, particularly with the use of highly reactive reagents.8  These 
hazards can be avoided under continuous flow conditions due to increased 
temperature control and short residence times.47,48 
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3.2  Initial Synthetic Studies 
 
3.2.1  Preparation of 2,4-dichloro-5-fluoroacetophenone derivatives 
 We began our inquiry into the synthesis of the carboxylated quinolone by 
attempting an addition to 2,4-dichloro-5-fluoroacetophenone 60 with a variety of 
formate esters (Figure 10) to yield compound 61 indicated in Scheme 9.  A 
number of solvents and reflux conditions were evaluated, but with no observed 
condensation product by NMR. 
 
 60     61      56      62 
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Scheme 9.  Overview of the initial proposed synthesis of the carboxylated 
quinolone and conversion to ciprofloxacin  
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      65           66 
 
 
   67   68 
Figure 10.  Formates used in initial study49,50 
 
After considerable experimentation, we found that dimethylformamide dimethyl 
amide (DMF-DMA) could be condensed with the 2,4-dichloro-5-
fluoroacetophenone 60 with good yield as shown in Table 1, providing an 
analogous intermediate. 
 
Table 1.  Reaction studies for the addition of DMF-DMA to 2,4-dichloro-5-
fluoroacetophenone. (Scheme 10) 
Entry Solvent Time Yield 
1 DMF 24 h 75% 
2 Toluene 24 h 86% 
3 Xylene 24 h 0% 
4 Toluene 48 h 87% 
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  60        69    70 
Scheme 10.  2,4-dichloro-5-fluoroacetophenone and DMF-DMF reaction51 
 
Based upon the data in the table, we can conclude that toluene was the most 
effective solvent for the addition reaction and running the reaction longer than 
24 hours did not greatly improve the yield.  The addition was slow and attempts 
to run it for a shorter time (18 hr) resulted in a considerable amount of 
unreacted starting material. 
3.2.2 Addition of cyclopropylamine and benzylamine 
 Upon acquiring a good yield of enaminone 70, we then sought out to 
exchange the dimethylamine with a carbocyclic amine (Scheme 11).  Drawing 
from the structure of Cipro, we were interested in carrying out this exchange 
with cyclopropylamine (CPA) 56.  The revised possible route to the carboxylated 
quinolone is outlined in Scheme 12.  After several attempts, shown in Table 2, 
we found the dimethylamine is not easily displaced by CPA.  Only trace amounts 
of product were seen by NMR. 
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   70         56   62 
Scheme 11. Proposed amine exchange reaction with cyclopropylamine 
 
Table 2.  Amine exchange reaction studies with cylcopropylamine (CPA).51,52  
(Scheme 11) 
Solvent Entry Base Equiv. CPA 
THF 1 none 1.5 
MeOH 2 none 3 
EtOH 3 K2CO3 (2 equiv) 1.5 
AcOH 4 K2CO3 (2 equiv) 3 
DMF 5 K2CO3 (5 equiv) 1.5 
 6 K2CO3 (5 equiv) 3 
 7 KOH (2 equiv) 1.5 
 8 KOH (2 equiv) 3 
Every entry was reacted in each of the five solvents separately. 
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       60       69              70      56       62 
 
       63     64 
Scheme 12.  Revised route to the carboxylated quinolone 
 
With this step presenting itself as a challenge, we pursued another option of 
carrying out the reaction with a higher molecular weight amine, benzylamine 
(Scheme 13), based on what was readily available in the laboratory. All of the 
same reaction conditions were studied as seen in Table 2 and similar results 
were obtained.  Only trace amounts of product were seen by NMR. 
 
 
70             71 
Scheme 13.  Amine exchange with benzylamine 
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98% 
3.3  Preparation of Nitroacetophenone Derivatives 
 Having found the amine exchange step unsuccessful, we began to focus 
on a different route, building a model system starting with a nitroacetophenone.  
Construction through this route presented a more affordable starting material 
through which to synthesize the 4-quinolone.  We employed all of the same 
reaction conditions used in the condensation of the formate esters with 
acetophenone 60 (section 3.2.1) and these efforts were unsuccessful. 
 
3.4  Preparation of Enaminone 74 and Transamination studies 
 Next we employed the best conditions used in the addition of DMF-DMA to 
acetophenone 60 (Table 1) and applied them to the nitroacetophenone 72.  We 
found, as shown in Scheme 14, was that the addition of DMF-DMA in toluene 
refluxed for 24 hours under nitrogen afforded exclusively enaminone 73 in a 
much more satisfactory yield of 98%. 
 
 
     72        69            73 
Scheme 14.  Synthesis of enaminone 7339,53 
 
 In order to expand the effectiveness and novelty of this route, we sought 
to develop the synthesis under flow conditions using a Vapourtec flow system. 
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Figure 11.  Vapourtec flow reactor54 
All reagents were premixed in a reagent bottle and flowed through the coiled 
reactor of 100°C at various flow rates.  The results were  impressive.  At a flow 
rate of 1 mL/min, we were able to obtain exclusively enaminone 73, drastically 
reducing the reaction time from 24 hours to just minutes. 
 Our earlier attempts to exchange the dimethylamine on compound 70 
proved to be a challenge, however we have high hopes for the exchange on 
enaminone 73 shown in Scheme 15.  With limited studies thus far, the 
transamination has yet to be completed.  Investigations into the role the 
substituents play on the effect of the exchange may give additional insight into 
resolving the issue. 
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    73  56        74 
Scheme 15.  Amine exchange with cyclopropylamine on enaminone 73 
 
3.5  Ring Closure through Reduction 
 The H-cube flow reactor has proven to be a useful resource towards the 
synthesis of our 4-quinolone.  As a hydrogen generator, the H-cube allows for 
catalytic hydrogenation in continuous flow as shown in Scheme 16.  With the H-
cube, the nitro group on enaminone 73 was reduced giving an aniline which 
then underwent intramolecular cyclization yielding a high purity product with 
10% Pd/C as the catalyst (Scheme 17). 
 
Scheme 16.  H-Cube Schematic 
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The best conditions, shown in Table 3, were obtained with a flow rate of 0.2 
mL/min, at room temperature, 1 bar and full hydrogen.  Attempts to carry out 
this reaction under conventional methods41,53 were unsuccessful, thus 
highlighting the effectiveness of utilizing a flow system to complete this 
synthesis. 
 
 
   73           75 
Scheme 17.  H-cube quinolone synthesis 
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Table 3.  H-cube Reaction Studies. 
Entry Flow Rate 
(mL/min) 
Temperature 
(°C) 
Pressure 
(bar) 
H2 Setting 
1 1 35 1 Controlled 
2 1 100 20 Controlled 
3 1 50 30 Controlled 
4 1 r.t. 40 Controlled 
5 1 100 20 Controlled 
6 1 r.t. 1 Full 
7 1 r.t. 1 Full 
8 0.5 r.t. 1 Full 
9 0.2 r.t. 1 Full 
Only entries 8 and 9 yielded product.  Entry 8 recovered a majority of starting materials. 
Entry 9 yielded pure product. 
 
The completion of this step provides a successful synthesis of 4-quinolones in 
flow from relatively inexpensive starting materials with high purity. 
 
3.6 Application Toward the Synthesis of Ciprofloxacin and Other 
Antibacterial Derivatives 
 One of the initial goals in exploring this area of chemistry was to develop 
a continuous route to the synthesis of quinolones that could be applied to the 
synthesis of other antibacterial drugs such as Ciprofloxacin.  The 4-quinolone 
ring system is an excellent scaffold for this.  It can be modified and manipulated 
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in a number of ways with functional groups to easily provide access to new and 
existing antibacterial drugs.  To expand on this idea, we further embarked on 
modifying the 4-quinolone system. 
 
3.6.1 Halogenation of the 4-quinolone at the 3-position 
  The first modification we explored was a halogenation at the 3-position of 
the 4-quinolone.  The purpose in this pursuit was to provide a shorter pathway 
toward the synthesis of carboxylated quinolone targets.  Limited results have 
been obtained, however ongoing investigations include the use of bromine 
(Scheme 18) or iodine (Scheme 19) as the halogens of choice.  
 
 
    75       76* 
 
Scheme 18.  Bromination of the 4-quinolone.41 
 
 
    75       77* 
 
Scheme 19.  Iodination of the 4-quinolone.55 
*yields for crude product 
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3.6.2  Methylation of the amine 
 Secondly, we took an interest in methylating the amine group.  Though 
there are a number of antibacterial drugs which do not require an R-substituted 
amine at the 1-postion, there are also a number of quinolone derivatives which 
contain an alkyl or cyclic alkane at that position.  The schemes we explored, 
Schemes 20 and 21, are shown below.  No results were finalized, however the 
resulting residue from the preliminary experiments showed mostly starting 
material by HPLC.  Optimization of reaction conditions is ongoing. 
 
 
      75         78 
Scheme 20.  Attempted route for methylation of the quinolone at the 1-
position.56 
 
 
       75        78 
Scheme 21.  Attempted route for methylation of the quinolone at the 1-
position.57 
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Chapter 4 
Experimental 
 
4.1 General Remarks 
All reagents and solvents were obtained from commercial sources and 
were used without further purification.  Melting points are not corrected.  1H 
NMR spectra were recorded on an Agilent-400 NHz NMR spectrometer.  High 
performance liquid chromatography was performed on a Waters Acquity H class 
liquid chromatograph. 
 The following abbreviations are used in the experimental section: s 
(singlet), d (doublet), t (triplet), q (quartet), dd (double of doublets), td (triplet 
of doublets), m (multiplet), HPLC (high performance liquid chromatography), mp 
(melting point), equiv (equivalents), mL (milliliters) and N2 (nitrogen). 
 
4.2 Experiments Pertaining the Starting Reagent 2,4-dichloro-5-
fluoroacetophenone  
 
a) Attempted addition of with ethylformate/ methylformate49,50 (section 
3.2.1) 
 
     79          80 
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 To a round bottom flask, equipped with a stir bar and a suspension of 
sodium ethoxide (1.0 equiv.) in dry ethyl ether, was added the 2,4-dichloro-5-
fluoroacetophenone (1.2 equiv.) and stirred for 15 min at room temperature.  
Ethylformate (1.2 equiv.) was added to the mixture and stirred for 3 hours at 
room temperature.  The resulting solution was evaporated under reduced 
pressure and the residue was taken up in dry DMF.  Ethyl bromide (2.0 equiv.) 
was added and the mixture was allowed to stir for 24 hours at room temperature 
before being poured into ice water and extracted with ethyl acetate.   The 
extracts were washed with water, dried over magnesium sulfate and evaporated.  
Upon evaporation, very little to no product was present and the NMR analysis 
showed no indication of the presence of the corresponding product.  The 
procedure was modified for methylformate using sodium methoxide and methyl 
iodide. 
 
b) Attempted addition of triethyl orthoformate/ trimethyl 
orthoformate49,50 
 2,4-dichloro-5-fluoroacetophenone (1.0 equiv.) was added to a mixture of 
triethyl orthoformate (1 equiv.) and acetic anhydride (1.5 equiv.) and was heated 
under reflux for 8 hours.   The crude mixture was concentrated under vacuum.  
NMR analysis revealed no loss of the methyl protons on the acetophenone. The 
same procedure was followed for trimethyl orthoformate. Furthermore, the 
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procedure was modified to explore the use of different solvents and longer 
reaction times to no avail. 
 
c) Preparation of 1-(2,4-dichlor-5-fluorophenyl)-3-(dimethylamino) 
prop-2-en-1-one (70)51 
 
 2,4-dichloro-5-fluoroacetophenone (1.0 equiv.) was dissolved in 5 mL of 
toluene with stirring. DMF-DMA (1.2 equiv.) was added and the solution was 
refluxed at 110°C under N2.  After 24 hours, the precipitate was filtered off and 
washed with hexanes.  The resulting product 70 was a yellow liquid that 
solidified upon cooling which was used directly in the next step. 1H NMR (DMSO-
d6): d = 7.99 (d, 1 H), 7.74 (d, 1 H), 7.57 (d, 1 H), 5.31 (d, 1 H), 3.15 (s, 3 H), 
2.89 (s, 3 H). 
 
d) Attempted transamination with cyclopropylamine (62)51,52 
 
 The product from 4.2 part (c) above was dissolved in THF and cooled in 
an ice bath to 5°C.  Cyclopropylamine (excess) was added to the mixture and 
O
F
Cl Cl N
O
F
Cl Cl NH
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stirred at 5°C for 1 hour.  The mixture was then concentrated under vacuum to 
yield a small amount of residue unidentified by NMR.  The procedure was 
modified with the bases shown in Table 2. 
 
e) Attempted transamination with benzylamine (71) 
 
 The product of 4.2 part (c) was dissolved in toluene with heating. 
Benzylamine (excess) was added and stirred at room temperature overnight.  
The mixture was concentrated under vacuum.  NMR showed exclusively starting 
material.  This procedure was modified using the solvents: acetic acid, methanol, 
and ethanol, separately, as well as heating at reflux overnight per solvent. 
Furthermore, we added sodium hydride with the thought of first deprotonating 
the benzylamine before introducing the enaminone. 
 
 
 
 
 
 
 
O
F
Cl Cl NH
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4.3 Experiments Pertaining to Starting Reagent Nitroacetophenone 
 
a) Attempted addition of the formates (section 3.3) 
 
    81     82 
 Compounds 81 and 82 were attempted according to the procedures from 
4.2 part (a) and part (b). 
 
b) Preparation of enaminone 7339,53 
 
Conventional method: O-nitroacetophenone 72 (1mL, 1.23 g, 7.4 mmol) was 
dissolved in 5 mL of toluene.  The solution was heated to 110°C (oil bath) while 
DMF-DMA (1.2 equiv.) was added.  Heating was continued at 110°C under reflux 
with a N2 balloon for 24 hours and then concentrated under vacuum.  The yellow 
liquid solidified upon cooling and was washed with hexanes. The solid was 
further dried under vacuum filtration giving 1.61g (98%) of 73 which was used 
directly in the next step.   
Flow method:  The Vapourtec was purged and filled with toluene (20 mL).  A 
mixture of 72 (2 mL, 2.46 g) and DMF-DMA (1 equiv) dissolved in toluene was 
O
NO2 O
O
NO2 O
O
NO2 N
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pumped through the Vapourtec at a flow rate of 1 ml/ min.  The  reaction 
temperature was held at 100°C.  The collected product precipitated out upon 
cooling in the collection vial.  The product was filtered, washed with hexanes and 
used directly in the next step. Mp=118-120°C, 1H NMR (CDCl3): d = 7.97 (d, J = 
6.9 Hz, 1 H), 7.64 (apparent t, J ≈ 7.5 Hz, 2 H), 7.47 (m, 2 H), 5.27 (d, J = 12.3 
Hz, 1 H), 3.20 (s, 3 H), 2.85 (s, 3 H). 
 
c) Attempted transamination with cyclopropylamine (74)51,52 
 
 Compound 73 was attempted from the product of 4.3 part (b) according 
to the procedure of 4.2 part (d). 
 
d) Preparation of the 4-quinolone (75) 
 
 The H-cube was purged and filled with ethanol.  Compound 73 (0.5 g, 
2.27 mmol) was dissolved in ethanol (25 mL) and acetic acid (5 mL) and then 
pumped into the reactor at a flow rate of 0.2 mL/ min at room temperature.  The 
reaction mixture was collected and the H-cube was purged with ethanol.  The 
O
NO2 NH
N
H
O
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solution was left in the fume hood overnight and the resulting yellow precipitate 
was filtered off to yield 75 as a pure compound revealed by HPLC and NMR. Mp 
206-208°C, 1H NMR (DMSO-d6): d = 6.25 (d, 1H, J = 7.1 Hz, H-3), 7.43 (td, 1H, 
J = 6.8 Hz, H-6), 7.59 (d,1H, J=8.2 Hz, H-8), 7.69 (td, 1H, J=8.1 Hz, H-7), 7.97 
(d, 1 H, J = 6.9 Hz, H-2), 8.22 (d, 1 H, J = 7.9 Hz, H-5) ppm. 
 
4.4 Experiments Pertaining to the Modification of the 4-Quinolone 
 
a) Preparation of the brominated 4-quinolone (76)41 
 
 A solution of sodium thiosufate (0.5 M, 25 mL) was first prepared.  4-
quinolone 75 was then refluxed for 10 minutes in acetic acid and bromine (1.0 
equiv.) was added dropwise at the same temperature.  The reaction mixture was 
stirred for 2 hours under reduced temperature and then allowed to cool to room 
temperature.  The suspension was poured over ice chips and further diluted with 
the sodium thiosulfate solution.  The resulting precipitate was filtered off, 
washed with water and air dried under vacuum filtration.  A beige solid was 
obtained (75%). 
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b) Preparation of the iodinated 4-quinolone (77)55 
 
 A mixture of 4-quinolone (1.0 equiv.), sodium carbonate (1.5 equiv), and 
iodine (1.5 equiv.) in dry THF was stirred under N2 for 6 hours at room 
temperature.  The mixture was then poured into a saturated solution of sodium 
thiosulfate and extracted 3 times with ethyl acetate.  The organic layer was dried 
over sodium sulfate and dried under vacuum to give a yellow solid (70%). 
 
c) Attempted methylation (scheme 20)56 
 
 Methyl iodide (10 equiv.) was added to a solution of 4-quinolone (1.0 
equiv.) and KOH (1.5 equiv.) in methanol.  The mixture was allowd to stir 
overnight at room temperature and the resulting precipitate was filtered off.  The 
remaining solvent was then evaporated and the resulting residue was analyzed 
by HPLC showing a large portion of starting material still present. 
 
d) Attempted methylation (scheme 21)57 
 The procedure for 4.4 part (c) was followed using 4-quinolone, methyl 
iodide, and sodium hydride in THF. 
N
O
H
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Chapter 5 
Conclusion  
 Quinolones have been studied extensively as antibacterial agents and the 
demand for more efficient routes to synthesize antibacterial drugs and their 
analogues is great.  Pharmaceutical companies are constantly searching for cost 
effective ways to make new and high quality compounds.  Accordingly, we have 
successfully synthesized the 4-quinolone under flow conditions. Our strategy 
brings forth a novel approach to the 4-quinolone ring system from the readily 
available and inexpensive nitroacetophenone. These efforts will provide a 
fundamental and reliable route to 4-quinolones which, in turn, can allow for the 
preparation of new antibacterial derivatives. 
 Although there are several existing methods available, there are no routes 
that synthesize 4-quinolones in flow.  Additionally, most syntheses focus on the 
carboxylated quinolone, where as the route described in this thesis leads to 3-
unsubstituted quinolones.  The result is a product that has increased diversity 
toward the accessibility of target structures, making the chemistry even more 
valuable. 
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